logo
AST SpaceMobile Is Go for Launch -- but Cash Burn Could Be a Problem

AST SpaceMobile Is Go for Launch -- but Cash Burn Could Be a Problem

Globe and Mail16-03-2025
AST SpaceMobile 's (NASDAQ: ASTS) stock took a big bounce after the company reported fourth-quarter results last week. At one point, shares of the satellite communications start-up were up 32% from their pre-earnings price, and even after Monday's steep price decline, they're still higher than they were before the report came out.
So that means the news was good, right? Revenues rising nicely, earnings ahead of analysts' forecasts, and so on?
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Well, not exactly.
At this point, the bottom line doesn't matter
Ahead of the report, analysts had been forecasting that AST would say it had lost $0.18 per share in Q4 on revenue of $2.4 million. AST did in fact lose $0.18 per share, but its revenue was only $1.9 million. For the year, the company missed on both top and bottom lines, losing $1.94 per share on $4.4 million in revenue.
So far, so bad. To be honest, though, earnings (or losses) aren't too significant for AST SpaceMobile right now. The company only has five comsats in orbit, and it hasn't yet received the go-ahead from the Federal Communications Commission to begin beta testing its direct-to-cell (DTC) communications service. That means any revenue the company might report today will be de minimis at best. It also means AST has essentially no chance of earning profits anytime soon.
In other words, if AST lost a bit more money than expected in 2024, that isn't necessarily a deal-breaker when it comes to the investment thesis. Much more important will be how quickly the company can build out its constellation, so it can begin beta testing, begin selling DTC cell service via partners, and begin booking some real revenue.
And there's good news on that front.
AST's BlueBirds of happiness
"The many pieces of our plan are rapidly coming into place," said AST CEO Abel Avellan in the Q4 release. For example, all five of the company's original BlueBird commercial satellites are now operational, and it's taking steps to put more satellites in orbit shortly.
Already, AST says it has 40 Block 2 BlueBirds in production, each more than three times the size of the five BlueBirds already up there. The company also said it's buying parts for at least 10 more satellites beyond that.
And AST has contracted with launch providers SpaceX, Blue Origin, and India's ISRO to launch a total of 60 satellites in 2025 and 2026.
Admittedly, it's unclear why these three sets of numbers don't quite line up -- why, for example, has it contracted to launch 20 more satellites than it currently has in production? One might surmise though, that AST is putting together whichever of the "many pieces of [its] plan," it can get a hold of, as fast as it can secure them, all in anticipation they'll fit together right in the end.
If nothing else, this speaks to management's clear intention to keep going big on its project, and to build out its capacity as quickly as possible without worrying that something might derail its plan. In furtherance of that plan, AST has secured agreements with 50 mobile network operators that serve nearly 3 billion subscribers total in more than 20 countries.
What could derail AST's plans
If there was just one detail I wish AST had addressed a bit better in its report, it would be how much of the above is already paid for, and how much more AST will have to spend. On the post-earnings conference call with analysts and investors, AST management said that, between cash on hand and the proceeds from its recent $460 million, 7-year convertible debt offering, AST now has nearly $1 billion in cash on its balance sheet.
Management asserted that this would be enough cash to keep it going for the next 12 months, and more specifically said it is "well positioned" to pay for the construction and launch of its "first threshold of 25 satellites."
Finally, management noted it expects to receive $43 million in revenue this year from the U.S. Space Force for a project it's working on for that agency. Between that contract and commercial revenue from its telecom partners, management expects to be free-cash-flow positive once it has 25 BlueBirds in orbit.
Again, all of this sounds great. Investors are probably glad to hear that after multiple rounds of dilutive secondary stock offerings and convertible debt issuance, AST is now in a position where it won't need to dilute them anymore in 2025.
Still, analysts polled by S&P Global Market Intelligence believe AST SpaceMobile will need to lay out nearly $1.1 billion in total capital expenditures over the next couple of years. So $1 billion may cover AST through 2025, but if it doesn't start making some money soon, it will almost certainly need to raise more cash in 2026.
Don't miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this.
On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $315,521!*
Apple: if you invested $1,000 when we doubled down in 2008, you'd have $40,476!*
Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $495,070!*
Right now, we're issuing 'Double Down' alerts for three incredible companies, and there may not be another chance like this anytime soon.
Continue »
*Stock Advisor returns as of March 14, 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders
ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders

Cision Canada

time28 minutes ago

  • Cision Canada

ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 23, 2025 /CNW/ -- ESSA Pharma Inc. (" ESSA," or the " Company") (NASDAQ: EPIX) today announced that, in connection with its previously announced business combination agreement with XenoTherapeutics, Inc. (" Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the " Transaction") all of the issued and outstanding common shares of ESSA (the " Common Shares"), the Company intends to apply to the Supreme Court of British Columbia (the " Court") on August 5, 2025 for (i) an interim order authorizing the holding of a special meeting to consider and approve the Transaction (the " Interim Order") and (ii) for an order authorizing the Company to make an initial cash distribution to its shareholders prior to the closing of the Transaction (the " Distribution Order" and together with the Interim Order, the " Orders"). ESSA is applying for the Distribution Order in order to expedite the distribution of cash to ESSA shareholders prior to the closing of the Transaction. In total, with the initial cash distribution, if authorized, and the cash payable upon closing of the Transaction, each ESSA shareholder is currently estimated to receive approximately US$1.91 per Common Share, exclusive of any contingent value rights payments shareholders are entitled to receive pursuant to the Transaction. The hearing for the Orders will take place at the courthouse of the Court at 800 Smithe Street, Vancouver, British Columbia at 9:45 a.m. (Pacific time) on August 5, 2025, or as soon thereafter as counsel may be heard, or at any other date and time and by any other method as the Court may direct. Any person that may be affected by any of the Orders sought may appear or be represented to present evidence or arguments at the hearing of the application for the Orders. The Supreme Court Civil Rules set out the prescribed forms for a Response to Petition (Form 67) and Affidavit (Form 109) to be filed with the Court. Response materials should also be sent to ESSA's counsel by mail or courier c/o Blake, Cassels & Graydon LLP, 1133 Melville Street, Suite 3500, The Stack, Vancouver, BC V6E 4E5 attention: Alexandra Luchenko, or by email to [email protected]. In accordance with the Rules of Court, ESSA intends to file its Petition Record on July 31, 2025, one full business day prior to the hearing. Response materials should be received by ESSA's counsel at the above address on or before 1:00 p.m. (Vancouver time) on July 31, 2025 to be included in the Petition Record. About ESSA Pharma Inc. ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit Forward Looking Statements This communication, and any related oral statements, contains certain information which, as presented, constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, " forward-looking statements"). Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial performance, containing words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and include, but are not limited to, statements regarding the proposed timing and completion of the Transaction, the amounts payable under the Transaction; ESSA's application to the Supreme Court of British Columbia for a reduction of capital and cash distribution prior to the closing the Transaction; the timing and receipt of securityholder, regulatory and court approvals of the Transaction; the satisfaction of the conditions to the completion of the Transaction and other statements that are not statements of historical facts. In this communication, these forward-looking statements are based on ESSA's current expectations, estimates and projections regarding, among other things, the expected date of closing of the Transaction and the potential benefits thereof, its business and industry, management's beliefs and certain assumptions made by ESSA, all of which are subject to change. Forward-looking statements are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby, including the consummation of the Transaction and the anticipated benefits thereof. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, regulatory, political and social uncertainties and contingencies. In making forward-looking statements, ESSA may make various material assumptions, including but not limited to (i) the completion of the Transaction on anticipated terms and timing, including obtaining required securityholder, regulatory and court approvals, and the satisfaction of other conditions to the completion of the Transaction; (ii) potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation or their respective directors or officers, including the effects of any outcomes related thereto; (iii) the risk that disruptions from the Transaction will harm ESSA's business, including current plans and operations; (iv) the ability of ESSA to retain and hire key personnel; (v) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction; (vi) continued availability of capital and financing and rating agency actions; (vii) legislative, regulatory and economic developments affecting ESSA's business; (viii) the accuracy of ESSA's financial projections; (ix) general business, market and economic conditions; (x) certain restrictions during the pendency of the Transaction that may impact ESSA's ability to pursue certain business opportunities or strategic transactions; (xi) unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, pandemics, outbreaks of war or hostilities, as well as ESSA's response to any of the aforementioned factors; (xii) significant transaction costs associated with the Transaction; (xiii) the possibility that the Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (xiv) competitive responses to the Transaction; (xv) the risks and uncertainties pertaining to ESSA's business, including those set forth in ESSA's Annual Report on Form 10-K dated December 17, 2024, under the heading "Risk Factors", a copy of which is available on ESSA's profile on EDGAR at and on SEDAR+ at and as otherwise disclosed from time to time on ESSA's EDGAR and SEDAR+ profiles; and (xvi) the risks and uncertainties that will be described in the proxy statement and management information circular for the Company's securityholders filed with the U.S. Securities and Exchange Commission (the " SEC," and such statement, the " Proxy Statement") available from the sources indicated above. These risks, as well as other risks associated with the Transaction, will be more fully discussed in the Proxy Statement. While the list of factors presented here is, and the list of factors to be presented in the Proxy Statement will be, considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material impact on ESSA's financial condition, results of operations, credit rating or liquidity. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable United States and Canadian securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements. Important Additional Information and Where to Find It In connection with the proposed Transaction between ESSA, Xeno and XOMA Royalty, ESSA will file with the SEC the Proxy Statement, the definitive version of which will be sent or provided to ESSA securityholders. ESSA may also file other documents with the SEC regarding the proposed Transaction. This document is not a substitute for the Proxy Statement or any other document which ESSA may file with the SEC. INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and securityholders may obtain free copies of the Proxy Statement (when it is available) and other documents that are filed or will be filed with the SEC by ESSA through the website maintained by the SEC at on SEDAR+ at ESSA's website at Participants in the Solicitation ESSA and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies from ESSA's shareholders in connection with the proposed Transaction. Additional information regarding the identity of the participants, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with the proposed Transaction (if and when they become available). Information relating to the foregoing can also be found in ESSA's proxy statement for its 2025 annual meeting of shareholders, which was filed with the SEC on January 22, 2025 (the " Annual Meeting Proxy Statement"). To the extent holdings of securities by potential participants (or the identity of such participants) have changed since the information printed in the Annual Meeting Proxy Statement, such information has been or will be reflected on ESSA's Statements of Change in Ownership on Forms 3 and 4 filed with the SEC. You may obtain free copies of these documents using the sources indicated above. or / Dan Moore [email protected] SOURCE ESSA Pharma Inc.

The Trade Desk Announces Date of Second Quarter 2025 Financial Results and Conference Call
The Trade Desk Announces Date of Second Quarter 2025 Financial Results and Conference Call

Globe and Mail

timean hour ago

  • Globe and Mail

The Trade Desk Announces Date of Second Quarter 2025 Financial Results and Conference Call

The Trade Desk, Inc. (NASDAQ: TTD), a provider of a global technology platform for buyers of advertising, today announced that it will release financial results for the second quarter ended June 30, 2025 after the market closes on Thursday, August 7, 2025. The Trade Desk will host a webcast and conference call to discuss second quarter financial results at 2:00 P.M. Pacific Time. Webcast and Conference Call Details When: August 7, 2025 at 2:00 P.M. Pacific Time (5:00 P.M. Eastern Time). Webcast: A live webcast of the call can be accessed from the Investor Relations section of The Trade Desk's website at Following the call, a replay will be available on the company's website. Dial-in: To access the call via telephone in North America, please dial 888-506-0062. For callers outside the United States, please dial 1-973-528-0011. Participants should reference the conference call ID code '760543' after dialing in. Audio replay: An audio replay of the call will be available beginning about two hours after the call. To listen to the replay in the United States, please dial 877-481-4010 (replay code: 52725). Outside the United States, please dial 1-919-882-2331 (replay code: 52725). The audio replay will be available via telephone until August 14, 2025. About The Trade Desk The Trade Desk™ is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize digital advertising campaigns across ad formats and devices. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across North America, Europe, and Asia Pacific. To learn more, visit or follow us on Facebook, Twitter, LinkedIn and YouTube.

CoreWeave Announces Date of Second Quarter 2025 Financial Results
CoreWeave Announces Date of Second Quarter 2025 Financial Results

Globe and Mail

timean hour ago

  • Globe and Mail

CoreWeave Announces Date of Second Quarter 2025 Financial Results

CoreWeave, Inc. (Nasdaq: CRWV) announced today that it will release second quarter 2025 financial results, after the market closes on Tuesday, August 12, 2025. CoreWeave will also host a conference call to discuss its results at 2:00 pm Pacific Time / 5:00 pm Eastern Time. The live webcast of the earnings conference call can be accessed at the CoreWeave Investor Relations website at A replay of the webcast will be available at the same website. About CoreWeave, Inc. CoreWeave, the AI Hyperscaler™, delivers a cloud platform of cutting-edge software powering the next wave of AI. The company's technology provides enterprises and leading AI labs with cloud solutions for accelerated computing. Since 2017, CoreWeave has operated a growing footprint of data centers across the US and Europe. Learn more at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store